Colchicine News and Research

RSS

3D nanomatrix vascular sheet model for high-throughput atherosclerosis drug testing

A groundbreaking 3D, three-layer nanomatrix vascular sheet that possesses multiple features of atherosclerosis has been applied for developing a high-throughput functional assay of drug candidates to treat this disease, University of Alabama at Birmingham researchers report in the journal Biomaterials.

12 Jan 2024

Colchicine does not reduce perioperative AF or MINS in major non-cardiac thoracic surgery

Colchicine does not significantly reduce perioperative atrial fibrillation (AF) or myocardial injury after non-cardiac surgery (MINS) in patients undergoing major non-cardiac thoracic surgery, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

Meta-analysis confirms 17 key metabolites as strong predictors of gout

Researchers summarized the use of metabolomics to detect metabolites in gout patients.

18 Jul 2023

Study: Spike in the price of gout drug colchicine linked to lower use and worse disease control

Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to $190.49 in 2011.

9 May 2023

Colchicine therapy benefits pediatric long COVID patients suffering from recurring fever

Researchers at National Jewish Health found that a subset of children suffering recurring fevers as a result of long COVID-19, benefited from a daily medication treatment commonly used for gout and periodic fever syndrome.

25 Apr 2023

Statin-related residual inflammation predicts cardiovascular events and mortality

A recent Lancet study assessed the importance of low-density lipoprotein cholesterol (LDLC) and high-sensitivity C-reactive protein (CRP) as risk predictors of cardiovascular death, cardiovascular events, and all-cause death among patients subjected to statins.

7 Mar 2023

A measure of residual inflammatory risk may be a powerful predictor of future cardiovascular events

New evidence released today from a study of 31,245 patients already taking statin therapy indicates that inflammation may be a more powerful predictor of risk of future cardiovascular events-;such as heart attack and stroke -; than "bad" cholesterol.

6 Mar 2023

Activating or deactivating drugs with the help of light

Scientists at the Paul Scherrer Institute PSI have used the Swiss X-ray free-electron laser SwissFEL and the Swiss Light Source SLS to make a film that could give a decisive boost to developing a new type of drug.

20 Feb 2023

Common psychiatric medications can give some protection against COVID-19

A new meta-analysis shows that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing the strongest effect.

16 Dec 2022

Gout flares associated with subsequent cardiovascular events

Experts at the University of Nottingham, in collaboration with experts at Keele University, have found that the risk of heart attacks and strokes temporarily increases in the four months after a gout flare.

2 Aug 2022

Oral Nirmatrelvir's effects on long COVID symptoms

In a recent study posted to the Research Square* preprint server, researchers at the University of California, San Francisco, examined the cases of three individuals who received nirmatrelvir/ritonavir antiviral therapy at different stages following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

4 May 2022

Safety profile of colchicine in COVID-19 patients

Researchers evaluated the use of colchicine in COVID-19 patients.

11 Apr 2022

Smoking cessation could help heart disease patients gain five years of healthy life

Smoking cessation adds the same number of heart disease-free years to life as three preventive medications combined, according to research presented at ESC Preventive Cardiology 2022, a scientific congress of the European Society of Cardiology.

7 Apr 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

Researchers identify first known patients with BUB1 biallelic mutations

A new study published in Science Advances described the first two patients known to have mutations in both copies of BUB1, a critical gene for cell division.

20 Jan 2022

Anti-inflammatory drug used to treat gout does not reduce the risk of COVID-19 mortality

Colchicine, a cheap anti-inflammatory drug normally used to treat gout, doesn't lessen COVID-19 severity or stave off the risk of death from the infection in hospital patients, finds a pooled analysis of the available evidence, published in the open access journal RMD Open.

23 Nov 2021

Study shows risk of MIS-C post mRNA vaccination against COVID-19 in children with autoimmune complications

Researchers discuss two cases of MIS-V after the patients had received the SARS-CoV-2 vaccine from Pfizer/BioNTech (BNT162b2).

23 Nov 2021

Is gout a risk factor for COVID-19?

A team of international scientists has recently determined the association between gout and risk of coronavirus disease 2019 (COVID-19) related death in a large cohort of patients. Their findings reveal that gout can significantly increase the risk of COVID-19 and related mortality, with women having a higher risk than men. The study is currently available on the medRxiv* preprint server.

4 Oct 2021

Dispensing of hydroxychloroquine and ivermectin in Australia jumped in first year of COVID

A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.

3 Oct 2021